GRI Bio, Inc. (GRI)
Nasdaq: GRI · Pharmaceutical Preparations · La Jolla, CA · filing with the SEC since 2020
Filings
334 filings since 2017 beside 69 insider forms · and emerging growth company · read from EDGAR on Nov 13, 2026Due next and emerging growth company
10-Q
Quarterly report for the quarter ending Sep 30, 2026Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by Nov 14, 2026
10-K
Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Mar 31, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. The proxy statement was last filed Sep 28, 2026.
Filings a yearinsider forms included
8535391898029
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 3 times in the last 36 months, the newest Nov 4, 2026.Listing warning from its exchange (8-K item 3.01): 9 times in the last 36 months, the newest Jan 16, 2026.Auditor change (8-K item 4.01): 1 time in the last 36 months, the newest Apr 16, 2025.SEC letters: 21 in the last 36 months, the newest Jan 30, 2026.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Nov 4, 2026
8-K items 5.02, 5.07, 9.01
Officer or director change; Shareholder vote · Current report
Sep 8, 2026
8-K items 7.01, 8.01, 9.01
Investor disclosure (Regulation FD); Other event · Current report
Jan 21, 2026
8-K items 3.03, 5.03, 8.01, 9.01
Change to shareholders' rights; Charter, bylaw or fiscal-year change; Other event · Current report
40 of 334 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.